Generic Advair's Labeling Variation Stems From Permissible Design Differences, US FDA Says

Patient instructions for use of Mylan’s fluticasone/salmeterol generic are noticeably different from GSK’s reference listed drug but fall within the ‘different manufacturers’ exception to the ‘same labeling’ requirement.

Concept of absolute parity with two same size balls but different color in perfect balance on a balance.

The US FDA’s approval of Mylan NV’s Wixela Inhub (fluticasone propionate/salmeterol) with patient instructions for use that are noticeably different from the reference product, GlaxoSmithKline PLC’s Advair Diskus, reflects the agency’s willingness to accept certain device design and labeling differences in the complex generics space.

The variation in instructions for use between Advair Diskus and Wixela Inhub stem from permissible design differences between the products’ user interfaces and are allowable under the “different manufacturers” exception to the “same labeling” requirement, FDA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By 

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

More from Biosimilars & Generics